Niaid preclinical development support; synthesize and produce HIV-1 envelope glycpeptide immunogen nanoparticle vaccine(s)
Ended Awarded Last action
- Contract number
- 75N93018F00005
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,959,434
Award facts
- Opportunity
-
- NIHAI2015035 Solicitation number
- Contract value 100% obligated
- $2,959,434.41 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $43,368 | |
| Funding Only Action | -$19,430 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $1,069,648 | |
| Original award | $1,865,848 |
About this award
This federal contract award, valued at $2,959,434.41, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL). The contract is for the synthesis and production of an HIV-1 envelope glycopeptide immunogen nanoparticle vaccine as part of NIAID's Preclinical Development Support program. This is a cost-plus-fixed-fee delivery order contract with an ultimate completion date of October 10, 2024. The contract does not have a set-aside designation, indicating that ABL, a foreign-owned, for-profit manufacturer of goods, was selected based on its capabilities in biopharmaceutical research and development services. ABL has previously supported various NIAID, National Cancer Institute (NCI), and National Institute of Neurological Disorders and Stroke (NINDS) programs through contract and grant awards, showcasing its expertise in developing medical countermeasures for infectious diseases and other health conditions.
Quick answers
Who was awarded contract 75N93018F00005?
75N93018F00005 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 12, 2018.
How much is contract 75N93018F00005 worth?
The government has obligated $2,959,434 on 75N93018F00005.
Is contract 75N93018F00005 an order under another contract?
Yes. 75N93018F00005 is a delivery order under HHSN272201700010I, an indefinite delivery contract.
Was contract 75N93018F00005 competed?
The extent of competition for 75N93018F00005 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award